Early research (Phase 1)Study completedNCT00001043
What this trial is testing
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
Who this might be right for
HIV InfectionsHIV Seronegativity
National Institute of Allergy and Infectious Diseases (NIAID) 20